CureVac NV
NASDAQ:CVAC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CureVac NV
Revenue
CureVac NV
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CureVac NV
NASDAQ:CVAC
|
Revenue
€535.2m
|
CAGR 3-Years
73%
|
CAGR 5-Years
98%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Revenue
€2.9B
|
CAGR 3-Years
-45%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Revenue
€48.3m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Revenue
€635.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
1%
|
|
|
Heidelberg Pharma AG
XETRA:HPHA
|
Revenue
€1.5m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Formycon AG
XETRA:FYB
|
Revenue
€44.5m
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
CureVac NV
Glance View
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.
See Also
What is CureVac NV's Revenue?
Revenue
535.2m
EUR
Based on the financial report for Dec 31, 2024, CureVac NV's Revenue amounts to 535.2m EUR.
What is CureVac NV's Revenue growth rate?
Revenue CAGR 5Y
98%
Over the last year, the Revenue growth was 896%. The average annual Revenue growth rates for CureVac NV have been 73% over the past three years , 98% over the past five years .
